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population of 65.8 million inhabitants. Mar-
kets are to be divided between hospital and 
pharmacy markets and special rules apply to 
innovative pharmaceuticals in both markets. 
In this regard, the growth by around 1.3% of 
the spending on pharmaceuticals expressed 
in manufacturer’s price excluding VAT in 
2010 was mainly driven by hospital medi-
cines purchases (+6%). In the same time, the 
manufacturer’s price excluding VAT of reim-
bursable pharmaceuticals sold in pharmacies 
increased by 0.5% compared to 2009 [3].
Over the last years, many cost-containment 
measures were implemented by the govern-
ment leading to drastic price-cuts. New para-
digms and healthcare models are emerging 
and health technology assessments are in-
creasingly taken into consideration. The De-
bré-Even [4] report following the Mediator 
controversy and the consultation process on 
medicinal products (so-called Assises du Mé-
dicament [5]) were the basis for an extensive 
reform aiming at fostering safety reporting 
on medicinal products and medical devices. 
The reform consists of three pillars which are 
the prevention of conflicts of interests and 
the transparency of decisions, the regulation 
of off-label use and the promotion of better 
trained and informed health professionals.
INTRODUCTION
The French system for pricing and reim-
bursement for pharmaceutical innovation 
has been influential for the new German 
system of Early Benefit Assessment under § 
35a SGB V and for the new mandatory price 
negotiation for all innovative pharmaceuti-
cals under paragraph 130b of the Sozialge-
setzbuch V (SGB V). The following review 
describes the French system in general and 
analyses the developments and changes by 
the recent French healthcare reform. Inno-
vative pharmaceuticals in France have been 
subject for a long-time to price-control and 
cost-containment measures. France initiated 
a concept of an evaluation of medical benefit 
by cost-containment bodies and mandatory 
price negotiations even in 2004 when Germa-
ny was still abandoning the concept of price 
negotiation. While Germany copied part of 
the French system of price negotiation, it has 
not enacted any direct restriction on the vol-
ume of sales in the AMNOG reform.
France has the second biggest rank in terms 
of healthcare spending after the US. Phar-
maceuticals represented around 19% of the 
budget of the Health Insurance funds in 2009 
[1]. The average ratio of health spending to 
GDP was around 11.2% in 2008 [2] for a 
Corresponding author
Dr. Alexander Natz, LL.M.
Bundesverband der 
Pharmazeutischen 
Industrie e.V. (BPI)
Rue du Commerce 31
1000 Brussels (Belgium)
anatz@bpi.de
Disclosure
The authors have no 
financial competing 
interest to declare
ABSTRACT
Over the last years, many cost-containment measures were implemented by the government leading to drastic price-cuts. 
New paradigms and healthcare models are emerging and health technology assessments are increasingly taken into con-
sideration. France has the second biggest rank in terms of healthcare spending after the US. Pharmaceuticals represented 
around 19% of the budget of the Health Insurance funds in 2009. In France, innovative pharmaceuticals have been subject 
for a long-time to price-control and cost-containment measures. The present review provides a general description of the 
French health care system, analyzing the developments and changes by the recent French health care reform.
Keywords
French healthcare reform; Pricing; Reimbursement; Innovative pharmaceuticals
Pricing and reimbursement 
of innovative pharmaceuticals 
in France and the new 
healthcare reform
Alexander Natz 1, Marie-Geneviève Campion 1
1 European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Brussels, Belgium
REVIEW
Farmeconomia. Health economics and therapeutic pathways 2012; 13(2): 49-60
© SEEd All rights reserved50 Farmeconomia. Health economics and therapeutic pathways 2012; 13(2)
Pricing and reimbursement of innovative pharmaceuticals in France and the new healthcare reform
regulatory authorities with proper informa-
tion for price setting based on scientific ex-
pertise to encouraging good practices and the 
proper use of pharmaceuticals. In this regard, 
the HAS cooperates on a regular basis with 
the IQWIG in Germany [17] and the NICE 
in the United-Kingdom [18] regarding the 
exchange of good practices and the sharing 
of health technology assessment studies [19].
Within the HAS, the Transparency Commis-
sion (Commission de la Transparence) [20] 
is composed of independent scientists and 
is in charge of assessing pharmaceuticals on 
the basis of a scientific medico-economic and 
public health assessment [21]. It assesses in 
depth the medical benefit of pharmaceuticals 
(Service Médical Rendu, SMR) and the inno-
vation level by assessing the improvement of 
the medical benefit (Amélioration du Service 
Médical Rendu, ASMR) compared to alter-
native products [22]. HAS can thus be com-
pared to the German IQWIG.
The other institution created by the healthcare 
reform of 2004 is the UNCAM [23] which 
unites the main health insurance funds, espe-
cially the biggest payer, the main regime for 
public and private employees (Caisse Natio-
nale d’Assurance Maladie des Travailleurs 
Salariés, CNAMTS [24]). The UNCAM is 
also in charge of the reimbursement policy 
and determines the products to be reimbursed 
and their respective reimbursement rate. UN-
CAM can thus be compared to the GKV-Spit-
zenverband in Germany.
The healthcare reform “Hospital, Health, Pa-
tients and Territories” of 2009 created a new 
kind of local stakeholder, the Health Region-
al Agencies (Agences Régionales de Santé, 
ARS) which role is to steer and implement 
national healthcare policies in regions.
Major stakeholder associations
Pharmaceutical companies which are repre-
sented by the LEEM [25] as well as physi-
cians and pharmacists grouped in profession-
al organizations (respectively in the Ordre 
des Médecins [26] and the Ordre des Phar-
maciens [27]) are also important in the leg-
islative process [28]. For example the LEEM 
sets out the general framework together with 
the CEPS for sales growth pricing and the 
promotion of medicinal products.
Legislative and regulatory 
framework
Link between the pricing-procedure 
and the reimbursement status
The pricing procedure which is linked to the 
reimbursement status of the pharmaceutical 
is set out in the Social Security Code. The 
law provides that pharmaceuticals without 
THE PHARMACY MARKET
Institutional framework
Central and independent 
regulatory bodies, the ANSM 
(ex-AFSSAPS) and the CEPS
Among the main institutional stakeholders, 
the French Health Products Safety Agency 
[6] (Agence Française de Sécurité Sanitaire 
des Produits de Santé, AFSSAPS) which 
is under supervision of the French Health 
Ministry [7] is responsible for marketing au-
thorizations, pharmacovigilance of national 
authorized pharmaceuticals and inspections. 
The recent healthcare reform which was en-
acted on the 29th December 2011 provides 
among other things to change the name of 
the AFSSAPS into the National Agency for 
Medicines Safety (Agence Nationale de Sé-
curité du Médicament, ANSM). The ANSM 
will be financed through taxes and charges 
from the pharmaceutical industry.
The Healthcare Products Pricing Commit-
tee [8] (Comité Economique des Produits 
de Santé, CEPS), which consists of officials 
from different ministries (Health, Social Se-
curity, Competition and Industry) [9] and 
health insurance funds, is in charge of the 
pricing of pharmaceuticals for human use 
[10]. Its missions are to negotiate in line with 
the ministerial policy a Framework Agree-
ment (Accord-cadre)  with the pharmaceuti-
cal industry [11] and to set prices. It is also 
entitled to sign with each pharmaceutical 
company or group of companies a contrac-
tual agreement for a period of maximum 4 
years determining e.g. the retail price of the 
pharmaceutical and the price trend, the pos-
sible rebates as well as the commitments of 
the company to promote a good use of the 
pharmaceutical and to respect sales volumes. 
It also provides for the conditions and mo-
dalities regarding pharmaco-epidemiological 
post-authorization studies [12].
Bodies created by the last healthcare 
reforms, the HAS and the UNCAM
The healthcare insurance reform of 2004 [13] 
brought comprehensive changes in the insti-
tutional framework of pricing and reimburse-
ment decisions. It created more cohesion be-
tween the government’s pricing decision and 
reimbursement policies and strengthened the 
role of the CEPS in this regard. Two new in-
stitutions were created, the French National 
Authority for Health (Haute Autorité de 
Santé, HAS) [14] and the National Union of 
Health Insurers (Union Nationale des Caiss-
es d’ Assurance Maladie, UNCAM) [15].
The HAS [16] is an independent public body. 
Its missions range from providing health 
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a convention within 75 days after the assess-
ment of the Transparency Commission [32]. 
In case of a rejection by the pharmaceutical 
company, the CEPS is obliged to examine 
the counter-proposal [33]. The ex-factory 
price is set by means of a contract which is 
signed for 4 years between the CEPS and the 
pharmaceutical company [34]. In case the 
negotiations fail, the price is set by decree 
of the ministers for Social Security, Health 
and Economy. CEPS is thus a powerful and 
crucial decision maker for pricing in France. 
Even though CEPS’ decision depends on the 
ASMR rating, it has a wide discretion regard-
ing the first pricing proposal. This means by 
contrast that – like in Germany – the negotia-
tion power of the pharmaceutical company is 
limited.
For innovative pharmaceuticals with an 
ASMR IV and I to III rating, the article 4 of 
the Framework Agreement provides for a pe-
riod of 5 years that the price level will not be 
lower than the price level in the four main 
countries: Germany, Italy, Spain and the U.K. 
Medicines having been granted an extension 
of indication with an ASMR rating from I to 
III and pediatric medicines which have real-
ized studies based on a pediatric investiga-
tion plan benefit from an extension of one 
year. Those measures aiming at promoting 
transparency and incremental innovation do 
not include all products with an ASMR IV.
Fast-track procedure of price 
notification for innovative 
pharmaceuticals
A special fast-track-procedure of notification 
for innovative pharmaceuticals is provided 
by law since 2003 [35] in order to facilitate 
their pricing and reimbursement process.
The Framework Agreement considers as in-
novative pharmaceuticals with an ASMR I, II 
and III rating and IV under some strict condi-
tions [36]. In this fast-track procedure, right 
after the granting of the ASMR by the Trans-
parency Commission, the manufacturer pro-
poses a price that is de facto accepted if the 
CEPS does not object it within two working 
weeks. The convention is then signed within 
48 hours. Otherwise, the normal application 
procedure applies. The price notified by the 
manufacturer should be in line with the ex-
isting price in Italy, Germany, Spain and the 
United-Kingdom. At the same time, pharma-
ceutical companies also commit to certain 
conditions concerning price revision, sales 
volumes, studies and information sharing 
related to the pharmaceutical product [37]. 
However, this procedure is not frequently 
used in practice and corresponds to a nar-
row definition of innovative pharmaceuticals 
any ASMR rating or implying no savings on 
medical treatment costs are not reimbursed 
by health insurance funds. Their price can 
be set freely but the reimbursement by the 
health insurance funds is prohibited [29]. The 
general price negotiation scheme for pharma-
ceuticals with an ASMR goes through differ-
ent stages [30]. The pricing-process begins 
with pharmaceutical companies submitting 
their applications simultaneously to both the 
CEPS and the Transparency Commission.
The price fixing decision of the CEPS con-
siders the medicines market in a compre-
hensive way. It takes into account the direct 
and indirect consequences of the price of the 
pharmaceutical on price structures within a 
single group and among different therapeutic 
groups, the economic consequences associ-
ated with reimbursement for the health in-
surance funds [31] and the long-term conse-
quences for future pharmaceuticals with the 
same indication [3].
In practice, the ex-factory price set by the 
CEPS is based on the ASMR rating granted 
by the Transparency Commission, the ex-
pected sales of the pharmaceutical and the 
prices of pharmaceuticals in other EU Mem-
ber States (external reference pricing) as well 
as the price of possible alternative therapies 
in France.
ASMR ratings are grouped in 5 main classes:
 - ASMR I rating is granted for medicinal 
products bringing a major therapeutic 
value;
 - ASMR II for medicinal products rep-
resenting a significant improvement in 
terms of efficacy and/or reduction of ad-
verse effects compared to existing alter-
natives;
 - ASMR III for a modest improvement;
 - ASMR IV rating for a minimum improve-
ment;
 - ASMR V for medicinal products without 
any therapeutic value but still being rec-
ommended to be registered on the posi-
tive list for reimbursement with a price 
criterion which does not lead to any non-
justified expenses.
Regarding external reference pricing, no for-
mal procedure exists. Pharmaceutical com-
panies are requested to provide the price of 
the pharmaceutical in question in other EU 
member states so that prices stay in line with 
the average price in the EU.
After the CEPS took its decision regarding 
the price, it formulates a proposal which 
is then negotiated with the pharmaceuti-
cal company. For pharmaceuticals having 
been granted an ASMR rating at least equal 
to level IV, the CEPS is committed to make 
the pharmaceutical company a proposal for 
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having been granted an ASMR I and II rating 
are exempted from claw-back for respective-
ly 36 and 24 months. ASMR III and IV rating 
have a respective 50% and 25% exemption 
for 24 months.
Price review clauses
Price review clauses are also foreseen in 
France [45]. Two main price review clause 
categories exist. The first one, “daily treat-
ment clauses”, covers situations where time 
and usage do not confirm the assumptions 
made when setting the price of the pharma-
ceutical. It results that the real cost per pa-
tient is inconsistent with the one that was 
agreed between the CEPS and the company. 
The second situation corresponds to “volume 
clauses” which ensure that the volumes of 
the pharmaceutical sold stay in line with the 
established target patient group assumed [3].
Additionally to the price review clauses, 
prices may be reviewed at the initiative of the 
CEPS when the registration of the medicine 
is being renewed, when the growth spending 
for a pharmaceutical is not consistent with 
the ONDAM [46] or when scientific and 
epidemiological data in follow-up studies on 
real-life change significantly.
Conventional policy aimed at 
physician prescription
Introduced in the LFSS 2008 and developed 
by the UNCAM [47], the contract for the im-
provement of individual practices (Contrat 
d’Amélioration des Pratiques Individuelles, 
CAPI) is a voluntary incentive scheme de-
signed among others to control physicians’ 
prescription behavior [48]. The CAPI scheme 
aims at promoting diseases preventions, op-
timizing prescription of generic medicines 
and promoting less costly medicines demon-
strating an equal efficiency (e.g., antibiotics, 
statins, antihypertensive medicines, proton-
pump inhibitors, antidepressants and ACE 
inhibitors) [49]. A CAPI is signed for 3 years 
and can be terminated at anytime. Interme-
diary and final targets are common for all 
physicians but the remuneration of each phy-
sician depends on his initial prescribing situ-
ation and the annual progress with regards to 
the targets [50].
THE HOSPITAL MARKET
Institutional framework
Before 2004, prices for hospital pharmaceu-
ticals were set freely and were principally in-
fluenced by the volume bought by the hospital 
and its buying power. The LFSS law of 2004 
[51] changes this situation and the framework 
of the “Plan Hôpital 2007” [52] still sets out 
[38]. In 2010, two orphan drugs applied for 
the price notification and both were refused. 
In 2009, 3 pharmaceuticals applied for the 
price notification procedure. Only one, which 
had an ASMR IV rating and has a use which 
does not imply any additional cost compared 
to existing pharmaceuticals, was accepted.
The reimbursement procedure
After the agreement between the CEPS and 
the pharmaceutical company on the ex-factory 
price, the registration of pharmaceuticals on 
the positive list of reimbursable pharmaceuti-
cals [39] is decided on by the UNCAM, based 
on the SMR rating granted by the Transparen-
cy Commission [40]. The registration, which 
is published in the Official Journal, is valid 
for 5 years. After this period the SMR rating 
of the pharmaceutical is reassessed.
Corresponding to those SMR rating, four 
reimbursement rates (100%, 65%, 30% and 
15%) have been defined. Full reimburse-
ment is granted for pharmaceuticals which 
are identified as irreplaceable (signalized by 
a white crossed sticker) and for patients hav-
ing a medical treatment for a disease which is 
fully reimbursed [41].
Claw-back payments, price review 
clauses and conventional policy
While the final price of pharmaceuticals sold 
in pharmacies includes the fixed margin of 
the wholesalers and of the pharmacists as 
well as a VAT rate of 2.1%, the price set by 
the CEPS also varies due to claw-backs, price 
review clauses and contractual agreements.
Claw-back per pharmacotherapeutic 
class based on capped turnover
The Framework Agreement provides annual 
adjustments if sales of pharmaceuticals ex-
ceed the national objectives on healthcare 
spending (Objectifs nationaux des Dépenses 
d’Assurance Maladie, ONDAM) defined 
each year in the Social Security Financ-
ing Law (Loi de Financement de la Sécu-
rité Sociale, LFSS), the so-called “safeguard 
clause” [42]. Hereby claw-backs apply if the 
cumulative growth of sales of reimbursable 
pharmaceuticals exceeds the sales-weighted 
mean value of the “K” [43] growth rate defin-
ing the ceiling of the safeguard clause.
At the end of the year, pharmaceutical com-
panies must send to the CEPS a declaration 
which sums up the volume and actual turn-
over of sales for each medicinal product and 
pharmaceutical form. Quantitative claw-
backs consist of payments per pharmaco-
therapeutic class grouping and of payments 
based on the turnover of the firm.
Specific provisions are provided for innova-
tive pharmaceuticals [44]. Pharmaceuticals 
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adjusted by the VAT and by a flat-rate mark-
up to compensate for the costs of hospital 
pharmacies [58].
The reimbursement of hospital ambulatory 
pharmaceuticals is based on the public final 
price [59]. Incentives are given to hospitals 
to acquire pharmaceuticals to a lower price. 
If the price paid by the hospital is lower than 
the public final price, the gain is for the hos-
pital. Therefore, public tenders and buying 
power situations could increasingly become 
an issue in France in addition to abovemen-
tioned cost-containment measures.
Framework for certain innovative 
medicines reimbursable 
on top of the T2A
For certain innovative pharmaceuticals, es-
pecially orphan and pediatric drugs, phar-
maceutical firms must declare the price to 
the CEPS [60]. The pricing system of those 
pharmaceuticals differs significantly from 
other hospital pharmaceuticals and is derived 
to large extent from the system for pricing 
of innovative pharmaceuticals dispensed in 
pharmacies. Full reimbursement is granted 
on the basis of the public price provided the 
hospital legal representative signed a contract 
of good use (Contrat de Bon Usage, CBU) 
with the ARS [61].
In case of violation of the contract, the reim-
bursement may be lowered by 30% [62]. In 
any case the difference between the sum paid 
and the amount reimbursed to the hospital 
cannot be paid out-of-pocket by the patient. 
If the price paid by the hospital is lower than 
the submitted price, the gains are divided be-
tween the hospital and the health insurance 
funds.
Specific framework for medicines 
with an Authorization of 
Temporary Usage (ATU)
Autorisation Temporaire d’Utilisation (ATU) 
corresponds to an exceptional and temporary 
measure granted by the AFSSAPS for the 
treatment of serious or rare diseases in the 
absence of a suitable therapeutic alternative 
with a marketing authorization available in 
France when a positive benefit/risk ratio is 
assumed [63]. For a product with an ATU a 
marketing authorization does not exist. These 
pharmaceuticals may be authorized abroad 
or be still under development. An ATU can 
be intended for a single, named patient (so 
called “named-patient ATU”) or it can con-
cern a group of patients, treated and moni-
tored according to a protocol for therapeutic 
use and information collection (so-called 
“cohort ATU”).
While only hospitals pharmacies belonging 
to public or private health care institutions 
the main lines regarding the regulation of 
hospitals. The aim was especially to regulate 
the price of innovative medicines and hospi-
tal ambulatory medicines meaning medicines 
intended to be delivered to outpatients (so 
called médicaments rétrocédés) [53].
In this regard, the modalities regarding the 
price-setting of innovative medicines and 
hospital ambulatory pharmaceuticals have 
been defined in the hospital medicines Frame-
work Agreement which was signed by the 
CEPS and the LEEM on the March, 30th 2004 
and then merged with the general Framework 
Agreement on September, 25th 2008.
Legislative and regulatory 
framework for pricing 
and reimbursement
Pricing of hospital pharmaceuticals differs 
from pharmaceuticals dispensed in pharma-
cies once the assessment of the Transpar-
ency Commission has been issued. In the 
new general framework, the price of hospi-
tal medicines is set freely between the hos-
pital and pharmaceutical company. Funding 
for hospitals and reimbursement for hospital 
pharmaceuticals is based on an activity-based 
payment (Tarification à l’activité, T2A) by 
means of diagnosis related groups (Groupes 
homogènes de séjour, GHS) [54]. However, 
the Framework Agreement provides that 
pharmaceutical companies have to declare 
the hospital price they plan as well as the 
hospital price of the medicines in the main 
EU member states.
Three categories of hospital pharmaceuticals 
exist with a special price and reimbursement 
framework: hospital ambulatory medicinal 
products, innovative medicines and pharma-
ceuticals having been granted an Authoriza-
tion of Temporary Usage (Autorisation Tem-
poraire d’Utilisation, ATU).
Framework for hospital ambulatory 
medicinal products
In order to be delivered to outpatients, hos-
pital pharmaceuticals have to be registered 
on the list of retrocession [55]. Pharmaceu-
tical firms must submit the ex-factory price 
to the CEPS [56]. The CEPS may oppose 
to the company’s submitted price [57]. The 
submitted price may be too high compared 
to the price in the four main European coun-
tries or compared to the existing comparable 
alternatives in France. Opposition may also 
be on the grounds of the insufficiency of the 
commitments of the firm with regards e.g. to 
the quantities sold or the conditions given the 
marketing authorization indications. The fi-
nal price of hospital ambulatory pharmaceu-
ticals is made of the ex-factory price which is 
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granted a marketing authorization prior to 
2005 [70]. To that purpose, it defined an ap-
proach to determine the medicines to be reas-
sessed with priority. The entry in the process 
can be the result of either a signal of risk or 
loss of benefits, a renewal of the marketing 
authorization or of a systematic approach ac-
cording to automate and manual criteria2.
The ASMR rating
Primary consideration for price-setting is the 
ASMR of the pharmaceutical. Contrary to the 
SMR rating, the ASMR rating compares the 
therapeutic value of a pharmaceutical to the 
existing alternatives in the same therapeutic 
class and assesses the improvement brought.
In 2010, 40% of the medicinal products as-
sessed were granted an ASMR rating be-
tween I and IV. In particular, two medicinal 
products were granted an ASMR I rating, two 
an ASMR II, eight an ASMR III and twenty 
an ASMR IV rating [68].
Insights into the medico-economic 
evaluation of the HAS
The Economic and Public Health Commis-
sion of the HAS (Commission Evaluation 
Economique et Santé Publique, CEESP) was 
created on July, 1st 2008 [71]. The CEESP re-
groups 25 members from various disciplines 
and its missions are to bring an expertise for 
economic studies and to propose decisions 
to the HAS regarding e.g. the validation and 
diffusion of recommendations and medico-
economic opinions [72]. The main activities 
of the CEESP relate to the assessment of 
public policies (assessment of the benefits, 
risks and efficiency) and medico-economic 
assessment [73].
Three intervention levels have been defined 
by the CEESP to reinforce the efficiency of 
health strategies [74]. The first level consists 
in comparing two products for the same indi-
cation. If their efficiency and tolerance is the 
same, it will recommend the less expensive 
one. The second level which is implemented 
when a difference in terms of efficiency or 
tolerance exists, concerns a balancing of the 
benefit and costs of the respective pharma-
2 Automate criteria include medicines on the French market 
for at least 7 years, with a low or insufficient SMR, with a 
galenic form liable to result in an additional risk because of 
its particular bioavailability and medicines with a high or a 
very low sales volume. With regards to manual criteria, they 
require specific research about each medicine such as for 
example whether it has been withdrawn from the market in 
another European country, or whether it is associated with 
an identified or a potential risk. Each criterion is assigned 
a weighting. After having assessed each medicinal product 
in the light of each criterion, the AFSSAPS assigns each 
of the products a weighted score. Medicines with a higher 
score will be reassessed with priority. The finalization of the 
criteria and the screening started in September 2011
are authorized to supply ATU pharmaceu-
ticals, those medicines may be intended for 
exclusive use in hospital1 or may be sold to 
ambulatory patients. In this regard, nomina-
tive ATU products are deemed to be sold by 
hospital pharmacies to ambulatory patients. 
Cohort ATU products have to be registered 
on the retrocession list.
In both cases, the maximum price of phar-
maceuticals with an ATU must be submitted 
by the pharmaceutical company to the CEPS 
which makes these declarations public [64]. 
For medicines with an ATU which are in-
tended for hospital use only hospitals receive 
compensation through special endowments. 
Products with an ATU which are sold to am-
bulatory patients are fully reimbursed on the 
basis of their final price.
THE BENEFIT ASSESSMENT OF 
INNOVATIVE PHARMACEUTICALS
Focus on the ASMR and SMR rating
Key-criteria in setting the price and determin-
ing the reimbursement rate of pharmaceuti-
cals are the SMR and ASMR ratings given by 
the Transparency Commission that assesses 
the medical benefit and the innovation rate of 
the pharmaceutical. The level of those ratings 
is the basis of the reimbursement status and 
the price of the pharmaceutical.
The SMR rating
The SMR rating is used to determine the 
reimbursement level for a pharmaceutical 
[65]. It takes into account the efficacy of 
the pharmaceutical under assessment and its 
side effects, the characteristics of the disease 
it is indicated for, the existence of alterna-
tive therapies, the role of the pharmaceutical 
within the overall therapeutic strategy as well 
as the impact on public health [66]. Accord-
ing to the assessment of those criteria, differ-
ent levels of SMR rating have been defined: 
major or important therapeutic value, moder-
ate or low therapeutic value but enabling re-
imbursement and insufficient [67]. The SMR 
rating of a pharmaceutical is granted for 5 
years. In 2010, 89 SMR ratings have been 
granted among which 88% were of major, 
moderate or low therapeutic value [68].
After 5 years, the SMR of a pharmaceutical is 
reevaluated through the new data which have 
been gathered [69]. The AFSSAPS started re-
assessing in September 2011 the benefit/risk 
ratio of each medicinal product having been 
1 Exclusive use in hospital means that prescription, supply 
and administration of the medicines are carried out only 
within a health care institution
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new approach of the CEPS, an innovation 
does not imply high prices anymore. In this 
regard, N. Renaudin, who was the previous 
chairman of the CEPS, declared in 2009 
that prices should stop increasing, especially 
for orphan drugs. For him, pharmaceuticals 
which are considered as too costly should 
not be marketed [79].
The LFSS 2011 provides that medicines 
treating rare diseases with a turn-over exclu-
sive of tax over 30 million Euros are not ex-
empted anymore from the wholesalers’ tax, 
safeguard clause tax and promotion tax [80].
IMPACT OF THE REFORM 
ON THE STRENGTHENING 
OF THE SAFETY OF MEDICINES 
AND HEALTH PRODUCTS
The Mediator controversy which led to the 
publication of the Debré-Even report3 was 
the starting-point for an extensive reform 
which aims at fostering safety of medicines 
and health products and has an impact on the 
price and reimbursement framework of inno-
vative medicines in France.
Impact on the ATU system
With regard to the ATU system [81], the 
healthcare reform provides that an ATU ap-
plication has to be accompanied by a simul-
taneous demand for a marketing authorization 
or by an application for a cohort ATU or by 
clinical studies with the medicine for the same 
indication in France. ATU are granted for a 
limited period of time which can be renewed. 
Exceptions from these requirements are pro-
vided for particularly in cases where, under 
the current state of the therapeutic options 
available, serious consequences for the pa-
tients are highly likely or, when the medici-
nal product is no longer commercialized for 
a specific indication and there is a strong 
presumption that the product is efficient and 
safe for a different indication.The healthcare 
reform also introduces a mandatory system-
atic monitoring of patients regarding the tol-
erance and the efficacy of the product.
Impact on the off-label use
The healthcare reform strengthens regulation 
of off-label use which should be subject to 
3 The “Rapport de la mission sur la refonte du système 
français de contrôle de l’efficacité et de la sécurité des 
médicaments” [4] recommends a fundamental reform of 
the AFSSAPS which would be in charge of the Transpa-
rency Commission. The HAS would focus on its mission 
of defining global health strategies and regulating medical 
activity. It also recommends moving from the SMR rating for 
new molecule towards the ASMR rating so that medicines 
should be exclusively assessed by clinical comparison with 
an existing molecule
ceuticals. Finally, the third level corresponds 
to a “full” analysis” in which the efficiency 
and the associated costs of a product as well 
its organizational or ethical dimensions are 
taken into account. In this regard, a public 
consultation was launched from December 
2010 to January 2011 in order to explain the 
methods and process of the economic assess-
ment of the HAS which is essentially a com-
parative approach [75]. In 2010, it released 18 
medical assessments and 6 public health rec-
ommendations [68]. The LFSS 2012 provides 
in this regard that when the pricing committee 
does not take into account the assessment of 
the HAS while setting the price of a pharma-
ceutical, it has to justify its decision [76].
Challenges with actual 
price-setting for innovative 
pharmaceuticals
Price-cut and price limitation 
for innovative products
The CEPS recently gave a clear signal for a 
price-stop for certain pharmaceuticals. While 
it was common practice to give pharmaceuti-
cals having been granted a high ASMR rating 
a price advantage compared to the existing 
alternatives, the CEPS clearly signified that 
for expensive medicines additional costs for 
the health insurance funds were neither jus-
tified nor necessary as the access to market 
was sufficiently rewarding by itself [3]. In a 
speech hold in January 2012, Gilles Johanet, 
Chairman of the CEPS, explained that the 
savings of around 1 billion planned for 2012 
should not be reached through new price-cuts 
but by the limitation of the prescription of 
expensive products and via a logic of perfor-
mance and cost-containment in particular in 
the hospital sector [77].
The article 10bis of the Framework Agree-
ment already provides that the CEPS can 
oblige a pharmaceutical company commer-
cializing an orphan drug with annual costs per 
patient over 50,000 Euros, in return for a price 
which is internationally coherent, to treat all 
the patients entitled for the treatment without 
any restriction, for a fixed total-turn-over.
New economic paradigm 
for innovative pharmaceuticals
While the law provides a fast-track procedure 
of price notification for innovative pharma-
ceuticals, the practice shows that only a lim-
ited amount of products from 1 to 3 per year 
only are concerned [3].
Through different incentives frameworks, 
health regulatory authorities send signals to 
pharmaceutical companies about the prod-
ucts they want to encourage, and the disease 
areas they want to give priority [78]. In the 
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